Type

Journal Article

Authors

M Clynes
Y Liang
J Keenan

Subjects

Microbiology

Topics
cell line tumor drug therapy nasal septum tritium nose neoplasms carcinoma squamous cell deoxyglucose pharmacokinetics antimetabolites antineoplastic metabolism humans pharmacology glucose drug resistance neoplasm blotting western

Two-deoxyglucose as an anti-metabolite in human carcinoma cell line RPMI-2650 and drug-resistant variants. (2004)

Abstract The accumulation of 2-deoxyglucose (2-DG), a glycolytic inhibitor, was investigated in a human nasal carcinoma cell line, RPMI-2650 and two of its drug-resistant variants (selected with taxol and melphalan) to assess manipulation of glycolytic potential as a selective means of reducing resistance. 2-DG uptake was increased 3-fold and 9.9-fold in taxol- and melphalan-resistant variants of RPMI-2650, respectively. Two of the principal factors associated with increased 2-DG uptake, namely glucose transporters and hexokinase activity, were increased in the resistant variants. Other changes in glucose metabolism that may affect 2-DG as an antimetabolite were observed, including increases in glucose-6-phosphate dehydrogenase of 10-fold and 100-fold for taxol- and melphalan-resistant variants, respectively, suggesting higher pentose phosphate activity; increased glutamine utilisation and greater sensitivity to iodoacetic acid-induced depletion of ATP levels in the parent relative to the resistant variants.
Collections Ireland -> Dublin City University -> PubMed

Full list of authors on original publication

M Clynes, Y Liang, J Keenan

Experts in our system

1
Martin Clynes
Dublin City University
Total Publications: 209
 
2
Joanne Keenan
Dublin City University
Total Publications: 23